Overview
The business environment in the pharmaceutical industry is changing so fast that the Darwinian
concept of "adapt or die" is on the mind of every senior executive. New technologies have
increased the complexity of pharmaceutical research, regulatory policy shifts and an ever-shrinking
period of exclusivity threaten profitability, and pharmacogenomics and personalized medicine may
turn the old market structure on its head. How do pharma companies plan for this uncertainty?
This report highlights the main areas where corporate transformation can meet the demands of a
shifting competitive landscape and presents specific strategies that companies are using to address
these demands, including:
- Benchmarking performance in drug discovery and development to examine and optimize
workflow, capacity, and communication.
- Recognizing competitive advantage through effective acquisition integration.
- "Fail fast" policies that enable companies to eliminate problematic compounds before they
are promoted to expensive clinical trials.
- Assessment of technology value, evolutionary stage, and relevance to corporate goals.
- The role of outsourcing and CROs, as well as knowledge management, competitive
intelligence, and business process engineering.
- How pharmacogenomics will transform research, clinical trials, marketing, and health care
delivery.
View Cart
